Loss of CD138, a myeloma cell-specific transmembrane heparin sulphate proteoglycan, represents a marker for determining the induction of apoptosis in myeloma cells following drug treatment (Jourdan et al, 1998; Clendening et al, 2010). This evidence concerns the gene SDC1 and plasma cell myeloma.